Perspectives in the treatment of interstitial lung disease accompanied with anti-melanoma differentiation-associated gene 5-positive dermatomyositis

Int J Rheum Dis. 2024 May;27(5):e15201. doi: 10.1111/1756-185X.15201.

Authors

Hideaki Tsuji¹, Ran Nakashima¹, Tsuneyo Mimori^{1

2}

Affiliations

¹ Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
² Takeda Clinic for Rheumatic Diseases, Kyoto, Japan.

PMID: 38769940
DOI: 10.1111/1756-185X.15201

No abstract available

Keywords: autoantibody; dermatomyositis; idiopathic inflammatory myopathy; plasmapheresis.

Publication types

Letter
Case Reports
Editorial

MeSH terms

Autoantibodies / blood
Dermatomyositis* / complications
Dermatomyositis* / drug therapy
Dermatomyositis* / genetics
Female
Humans
Immunosuppressive Agents / therapeutic use
Interferon-Induced Helicase, IFIH1* / genetics
Interferon-Induced Helicase, IFIH1* / immunology
Lung Diseases, Interstitial* / complications
Lung Diseases, Interstitial* / drug therapy
Treatment Outcome

Substances

Autoantibodies
IFIH1 protein, human
Immunosuppressive Agents
Interferon-Induced Helicase, IFIH1